CurrentMedical Mutual - OhioPolicy N/A

Belimumab (Benlysta) — Coverage Criteria for Systemic Lupus Erythematosus and Lupus Nephritis

Defines Medical Mutual - Ohio prior authorization, coverage criteria, dosing, and site-of-care requirements for belimumab (Benlysta) for systemic lupus erythematosus and lupus nephritis for medical and pharmacy benefits.

Policy Summary

PayerMedical Mutual - Ohio

PolicyBelimumab (Benlysta) — Coverage Criteria for SLE and Lupus Nephritis

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateMay 31, 2011

Next Review DateJan 15, 2026

Key ActionObtain prior authorization when billing benlysta under the medical benefit (HCPCS J0490 or J3590) and submit required documentation to support medical necessity.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2FDA indications covered

6Initial approval (months)

12Extended approval (months)

J0490,J3590Prior auth HCPCS

>5 yrsMinimum age

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Belimumab (Benlysta)

Initial Therapy — SLE

Covered when ALL of the following are met

SLE initial coverage: I. Age > 5 years; AND II. Active, autoantibody-positive systemic lupus erythematosus despite >6 weeks trial of conventional medical therapy; AND III. SLE is active as documented by a SELENA-SLEDAI score >= 6 while on current treatment regimen; AND IV. Belimumab will be used in combination with conventional medical therapy (e.g., corticosteroids, antimalarials, or other immunosuppressants); AND V. Severe active central nervous system lupus erythematosus is not present; AND VI. Belimumab will not be used in combination with another biologic agent; AND VII. Site of care medical necessity is met

Autoantibody defined as positive ANA (titer >1:80) or anti-dsDNA >30 IU/mL

Dosing — SLE

Dosing requirements

SLE dosing: Intravenous: 10 mg/kg at 2-week intervals for the first 3 doses then every 4 weeks thereafter; administer as an IV infusion over 1 hour. Subcutaneous (adults): 200 mg once weekly. Subcutaneous (pediatrics): >=40 kg: 200 mg once weekly; 15 to <40 kg: 200 mg once every 2 weeks.

Reconstitute, dilute, and administer per product instructions

Initial Therapy — Lupus Nephritis

Covered when ALL of the following are met

Lupus nephritis initial coverage: I. Age > 5 years; AND II. Severe active central nervous system lupus erythematosus is not present; AND III. Belimumab will not be used in combination with another biologic agent; AND IV. Belimumab will be used in combination with conventional medical therapy; AND V. Patient has active lupus nephritis Class III, IV, or V confirmed by renal biopsy; AND VI. Confirmed diagnosis of SLE with at least 4 diagnostic features, one of which must include a positive autoantibody test (e.g., ANA); AND VII. Patient has failed to respond adequately to standard therapies including corticosteroids AND either cyclophosphamide or mycophenolate mofetil; AND VIII. Baseline measurement of one or more of the following: urine protein:creatinine ratio (uPCR), estimated glomerular filtration rate (eGFR), or urine protein; AND IX. Site of care medical necessity is met

Renewal requires response and disease stability/improvement by uPCR, eGFR, or urine protein and absence of unacceptable toxicity

Dosing — Lupus Nephritis

Dosing requirements

Lupus nephritis dosing: Intravenous: 10 mg/kg at 2-week intervals for the first 3 doses then every 4 weeks thereafter; administer as IV infusion over 1 hour. Subcutaneous (adults): 400 mg once weekly for 4 doses then 200 mg once weekly thereafter; patient may transition from IV to SC any time after completing first 2 IV doses and first SC dose given 1–2 weeks after last IV dose. Subcutaneous (pediatrics): >=40 kg: 400 mg once weekly for 4 doses then 200 mg once weekly; 15 to <40 kg: 200 mg once weekly for 4 doses then 200 mg once every 2 weeks.

First SC dose administered 1-2 weeks after last IV dose

Initial and Extended Approval

Authorization durations and renewal

Authorization periods: Initial approval: 6 months. Extended/renewal: approve an additional 12 months if the patient has responded to therapy as determined by the prescribing physician. For lupus nephritis specifically, renewal requires disease stability and/or improvement after 12 months as indicated by uPCR, eGFR, or urine protein and absence of unacceptable toxicity.

Response required for continuation

Coverage is not recommended for circumstances that are not specifically listed in the Recommended Authorization Criteria. The policy notes that Benlysta has not been shown to be effective, or there are limited or preliminary data or potential safety concerns, for conditions outside the stated criteria; the list of not-recommended conditions is not exhaustive and the criteria will be updated as new published data become available.

Use of belimumab for indications that do not meet the Recommended Authorization Criteria may be considered not medically necessary. The Company may deny reimbursement when the drug or services are determined to be not medically necessary, investigational or experimental, or not within the member's benefit scope. Providers should be prepared to supply additional documentation (patient records, test results, provider credentials) upon request to support medical necessity.

Coding, Scores, and Diagnostic Thresholds

HCPCS codes requiring prior approvalHCPCS

J0490	Injection, belimumab, 10 mg
J3590	Unclassified biologic

SELENA-SLEDAI score — threshold used for activity

SELENA-SLEDAI thresholdSELENA-SLEDAI score ≥ 6 while on current treatment regimen

ContextDefines active SLE for coverage determinations

Source noteRequired as part of initial SLE coverage criteria (patient must have active disease despite >6 weeks of conventional therapy)

ANA titer — autoantibody threshold

ANA titer thresholdAntinuclear antibody (ANA) titer > 1:80

RoleOne component of autoantibody-positive definition required for coverage

Alternate wording in diagnostic criteriaPositive ANA greater than laboratory reference range (one of 11 diagnostic SLE features)

anti-dsDNA — autoantibody threshold

Anti-dsDNA thresholdAnti-double-stranded DNA (anti-dsDNA) level > 30 IU/mL (or >2× laboratory reference range when specified)

Diagnostic roleAnti-dsDNA >2× lab reference is listed as an immunologic diagnostic feature of SLE

Coverage definitionPositive anti-dsDNA is part of the autoantibody-positive requirement for belimumab coverage

Provider Actions, Requirements, and Denial Risks

Prior Authorization

Prior Authorization Required — medical benefit billing and benefit interplay

Prior authorization is required for Benlysta when billed under the medical benefit. Submit prior approval requests for HCPCS J0490 and J3590. Prior approval requests that meet policy criteria may be authorized by a nurse reviewer; requests that do not meet criteria will be forwarded to a physician reviewer. Claims with these HCPCS codes may pend with Remark Code M3M or M4M.

HCPCS: J0490, J3590
Site-of-care requirements apply — administration restricted to non-hospital facility-based locations unless exception criteria met
Benlysta IV prior authorization must be submitted under the medical benefit

Step Therapy

Step Therapy Requirements — prior trials and failed therapy for SLE and lupus nephritis

Members must complete required step-therapy and prior trial requirements before initiating belimumab for SLE or lupus nephritis. For lupus nephritis, documentation must show failure to respond adequately to standard therapies including corticosteroids AND either cyclophosphamide or mycophenolate mofetil. For systemic lupus erythematosus, the patient must have active, autoantibody-positive disease despite >6 weeks trial of conventional medical therapy and belimumab must be used in combination with conventional therapy.

SLE: >6 weeks trial of conventional medical therapy required prior to belimumab
Lupus nephritis: failed trial of corticosteroids AND either cyclophosphamide or mycophenolate mofetil

Documentation Required

Required Supporting Documentation — examples and expectations

Provide complete clinical documentation to support medical necessity. Be prepared to supply patient records, test results, provider credentials, and objective disease activity and renal function measures on request. The Company may deny reimbursement if documentation is insufficient, the treatment is not medically necessary, investigational, or outside benefit scope.

Examples of documentation: SELENA-SLEDAI score (≥6 for SLE on current regimen), positive ANA (titer >1:80) or anti-dsDNA (>30 IU/mL)
Renal baseline and response measures: urine protein:creatinine ratio (uPCR), estimated glomerular filtration rate (eGFR), or urine protein
For lupus nephritis: anti-dsDNA greater than 2× lab reference range if by ELISA, and biopsy/renal testing as applicable
Evidence of treatment response at renewal (e.g., improved/stable uPCR or eGFR compared to baseline)
Site-of-care documentation if seeking hospital administration exception

Denial Risk

Documentation-Related Denial Risks — conditions that may lead to denial

Denials may occur when criteria are not met or documentation is insufficient. Common denial reasons include: lack of required prior trials or step-therapy failure documentation, absence of objective disease activity measures (e.g., SELENA-SLEDAI, anti-dsDNA), missing renal baseline or response data for lupus nephritis, use in combination with another biologic, or site-of-care noncompliance.

Not medically necessary or investigational
Insufficient documentation of prior therapies, disease activity, or renal metrics
Use with another biologic agent (not allowed)
Failure to meet site-of-care medical necessity or to document exception

OpenPayer

Belimumab (Benlysta) — Coverage Criteria for Systemic Lupus Erythematosus and Lupus Nephritis

Coverage Criteria for Belimumab (Benlysta)

Coding, Scores, and Diagnostic Thresholds

Provider Actions, Requirements, and Denial Risks

Background

Definitions and Clinical Thresholds